IL6 and psoriasis: The value of IL-6 as therapeutic target in several inflammatory and immune mediated has been postulated on psoriasis [53] and on atopic dermatitis, as demonstrated by data on Tocilizumab, a humanized monoclonal antibody directed against the IL-6 receptor, which in three case series demonstrated efficacy on pruritus and EASI index, in patients refractory to topical corticosteroid therapy and, in two cases, to cyclosporine [54].